教員・教室員について
准教授
名前 | 加藤 光次(かとう こうじ) |
---|---|
卒業年 | 1995(平成7)年 |
学位取得年月 | 2005年3月 医学博士学位取得 |
専門領域 | 血液内科学、造血幹細胞移植 |
資格 | 日本内科学会認定内科医・総合内科専門医・指導医 日本血液学会専門医・指導医・評議員 日本造血・免疫細胞療法学会認定医・評議員 日本HTLV-1学会 評議員 日本リンパ網内系学会 評議員 |
所属学会 | 日本内科学会、日本血液学会、日本造血・免疫細胞療法学会、日本輸血細胞治療学会、日本リンパ網内系学会、日本免疫学会、アメリカ血液学会、日本HTLV-1学会 |
略歴
1995年5月 |
県立宮崎病院内科、山口赤十字病院内科、北九州市立医療センター内科、九州大学病院第一内科、九州大学病院輸血部 |
---|---|
2002年5月 |
浜の町病院血液内科 |
2006年4月 |
米国ミシガン大学骨髄移植部門 研究員 |
2009年10月 |
九州大学病院血液腫瘍内科 助教 |
2017年4月 |
九州大学病院 血液・腫瘍・心血管内科 講師 |
2018年10月 |
九州大学病院 血液・腫瘍・心血管内科 診療准教授 |
2022年4月 | 九州大学大学院 病態修復内科学 准教授 現在に至る |
代表的業績
- Shimoda K, et al. Tyk2 Plays a Restricted Role in IFN Signaling, Although It Is Required for IL-12-Mediated T Cell Function.
Immunity 2000; 13: 561-571. - Shimoda K, et al. Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice.
Blood 2002; 99: 2094-2099. - Kato K, et al. Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth.
Br J Haematol. 2003; 123: 528-535. - Kato K, et al. Allogeneic bone marrow transplantation from unrelated HTLV-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan marrow donor program.
Biol Blood Marrow Transplant. 2007; 13: 90-99. - Kato K, et al. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.
Biol Blood Marrow Transplant. 2010; 16: 751-771. - Zhang Y, et al. Notch signaling is a critical regulator of allogeneic CD4+ T cell responses mediating graft-versus-host disease.
Blood 2011; 117: 299-308. - He S*, Kato K*, et al. Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells.
PLoS ONE. 2011: 6(5); e20107. (*contributed equally) - He S*, Kato K*, et al. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.
Blood. 2012; 119: 1274-1282. (*contributed equally) - Ishida T, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study.
Blood. 2012; 120: 1734-41. - Shima T, et al. Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation.
Blood. 2013; 121: 840-8. - Kato K, et al. Long-term remission after high-dose chemotherapy followed by auto-SCT as consolidation for intravascular large B-cell lymphoma.
Bone Marrow Transplant. 2014; 49: 1543-4. - Kato K, et al. Treatment of patients with adult T cell leukemia/lymphoma with cord blood transplantation: A Japanese nationwide retrospective survey.
Biol Blood Marrow Transplant. 2014; 20: 1968-74. - Uryu H, et al. α-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice.
Blood. 2015;125: 3014-23. - Sugio T*, Kato K*, et al. Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease.
Biol Blood Marrow Transplant. 2016; 22: 1608-1614. (*contributed equally) - Miyoshi H, et al. PD-L1 expression on neoplastic or stromal cell is respectively poor or good prognostic factor for adult T-cell leukemia/lymphoma.
Blood. 2016; 128: 1374-1381. - Fuji S, et al. Pretransplant anti-CCR4 antibody mogamulizumab against ATLL is associated with significantly increased risks of severe and steroid-refractory GVHD, non-relapse mortality and overall mortality.
J Clin Oncol. 2016; 34: 3426-3433. - Shimoji S, et al. Graft-versus-host disease targets ovary and causes female infertility in mice.
Blood. 2017; 129: 1216-1225. - Miyawaki K, et al. Identification of unipotent megakaryocyte progenitors in human hematopoiesis.
Blood. 2017; 129: 3332-3343. - Kawamoto K, et al. A distinct subtype of Epstein Barr virus positive T/NK-cell lymphoproliferative disorder: Adult patients with chronic active Epstein Barr virus infection-like features.
Haematologica. 2018; 103: 1018-1028. - Karube K, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
Leukemia. 2018; 32: 675-684. - Sugio T, et al. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS.
Blood Adv. 2018; 2: 2242-2252. - Kato K, et al. The outcome and characteristics of patients with relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation.
Hematol Oncol. 2019; 37: 54-61. - Miyazaki K, et al. CD5+ DLBCL Treatment Study Group. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study.
Haematologica. 2020; 105: 2308-2315. - Nakano N, et al. Chromosomal defects and survival in patients with adult T-cell leukemia/lymphoma after allogeneic HSCT.
Blood Adv. 2021; 5: 475-486. - Schuster SJ, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22: 1403-1415.
- Harada T, et al. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Br J Haematol. 2021; 194: 101-110.
- Nowakowski GS, et al. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2021; 39: 1317-1328.
- Kato K, et al. Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. Int J Clin Oncol. 2022; 27: 213-223.
- Bishop MR, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022; 386: 629-639.
- Fowler NH, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022; 28: 325-332.
- Miyawaki K, et al. A Germinal Center-Associated Microenvironmental Signature Reflects Malignant Phenotype and Outcome of DLBCL. Blood Adv. 2022 Epub ahead of print.